Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Safety and Efficacy of VAY736 in Patients With Primary Sjogren's Syndrome (pSS)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02962895
Recruitment Status : Active, not recruiting
First Posted : November 15, 2016
Last Update Posted : July 28, 2020
Sponsor:
Information provided by (Responsible Party):
Novartis ( Novartis Pharmaceuticals )

Brief Summary:
This study will determine the dose-response relationship of VAY736 for key efficacy and safety parameters

Condition or disease Intervention/treatment Phase
Primary Sjogren Syndrome Biological: VAY736 Other: Placebo Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 195 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Official Title: Study of Safety and Efficacy of Multiple VAY736 Doses in Patients With Moderate to Severe Primary Sjogren's Syndrome (pSS)
Actual Study Start Date : June 27, 2017
Actual Primary Completion Date : June 30, 2020
Estimated Study Completion Date : December 30, 2020

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: VAY736 dose 1
VAY736 low
Biological: VAY736
VAY736

Experimental: VAY736 dose 2
VAY736 medium
Biological: VAY736
VAY736

Experimental: VAY736 dose 3
VAY736 high
Biological: VAY736
VAY736

Placebo Comparator: Placebo
Placebo control
Other: Placebo
Placebo control




Primary Outcome Measures :
  1. Change in multi-dimensional disease activity [ Time Frame: 24 weeks ]
    Dose response measured by change multi-dimensional disease activity as assessed by the physician


Secondary Outcome Measures :
  1. Change in patient-reported disease activity measures [ Time Frame: 24 weeks ]
    Dose response measured by change in patient-reported disease activity measures

  2. Change in quality of life measure by PRO [ Time Frame: 24 weeks ]
    Change in quality of life measure by PRO

  3. Change in salivary gland function measure by flow rate [ Time Frame: 24 weeks ]
    salivary gland function measure by flow rate

  4. Incidence of Adverse events and Serious Adverse Events [ Time Frame: 24 weeks ]
    Number of participants with adverse events



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Fulfilled revised American European Consensus Group criteria for pSS
  • Seropositive at screening for anti-Ro/SSA antibodies
  • Screening ESSDAI value >=6 scored from 7 domains: articular, cutaneous, glandular, lymphoadenopathy, constitutional, biologic and hematologic.

Exclusion Criteria:

  • Secondary Sjogren's syndrome
  • Use of other investigational drugs
  • Active viral, bacterial or other infections
  • Positive hepatitis B, hepatitis C, HIV or tuberculosis test results at screening

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02962895


Locations
Show Show 56 study locations
Sponsors and Collaborators
Novartis Pharmaceuticals
Layout table for additonal information
Responsible Party: Novartis Pharmaceuticals
ClinicalTrials.gov Identifier: NCT02962895    
Other Study ID Numbers: CVAY736A2201
First Posted: November 15, 2016    Key Record Dates
Last Update Posted: July 28, 2020
Last Verified: July 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided
Plan Description:

Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.

This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com


Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Novartis ( Novartis Pharmaceuticals ):
Sjogren
VAY736
ianalumab
Additional relevant MeSH terms:
Layout table for MeSH terms
Sjogren's Syndrome
Syndrome
Disease
Pathologic Processes
Arthritis, Rheumatoid
Arthritis
Joint Diseases
Musculoskeletal Diseases
Rheumatic Diseases
Xerostomia
Salivary Gland Diseases
Mouth Diseases
Stomatognathic Diseases
Dry Eye Syndromes
Lacrimal Apparatus Diseases
Eye Diseases
Connective Tissue Diseases
Autoimmune Diseases
Immune System Diseases